Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.
2.

Diminazene aceturate: an antibacterial agent for Shiga-toxin-producing Escherichia coli O157:H7.

Wu SY, Park GY, Kim SH, Hulme J, An SS.

Drug Des Devel Ther. 2016 Oct 14;10:3363-3378.

3.

Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.

Ozaki M, Kang Y, Tan YS, Pavlov VI, Liu B, Boyle DC, Kushak RI, Skjoedt MO, Grabowski EF, Taira Y, Stahl GL.

Kidney Int. 2016 Oct;90(4):774-82. doi: 10.1016/j.kint.2016.05.011.

PMID:
27378476
4.

Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions.

Álvarez RS, Sacerdoti F, Jancic C, Paton AW, Paton JC, Ibarra C, Amaral MM.

PLoS One. 2016 Jun 23;11(6):e0158180. doi: 10.1371/journal.pone.0158180.

5.

Genotype Cluster Analysis in Pathogenic Escherichia coli Isolates Producing Different CDT Types.

Javadi M, Oloomi M, Bouzari S.

J Pathog. 2016;2016:9237127. doi: 10.1155/2016/9237127.

6.

Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Freedman SB, Xie J, Neufeld MS, Hamilton WL, Hartling L, Tarr PI; Alberta Provincial Pediatric Enteric Infection Team (APPETITE)..

Clin Infect Dis. 2016 May 15;62(10):1251-8. doi: 10.1093/cid/ciw099.

PMID:
26917812
7.

Complement, thrombotic microangiopathy and disseminated intravascular coagulation.

Kurosawa S, Stearns-Kurosawa DJ.

J Intensive Care. 2014 Dec 31;2(1):65. doi: 10.1186/s40560-014-0061-4. Review.

8.

Commensal E. coli Stx2 lysogens produce high levels of phages after spontaneous prophage induction.

Iversen H, L' Abée-Lund TM, Aspholm M, Arnesen LP, Lindbäck T.

Front Cell Infect Microbiol. 2015 Feb 3;5:5. doi: 10.3389/fcimb.2015.00005.

9.

Management of hemolytic uremic syndrome.

Kavanagh D, Raman S, Sheerin NS.

F1000Prime Rep. 2014 Dec 1;6:119. doi: 10.12703/P6-119. Review.

10.

Role of Shiga/Vero toxins in pathogenesis.

Obata F, Obrig T.

Microbiol Spectr. 2014 Jun;2(3). doi: 10.1128/microbiolspec.EHEC-0005-2013. Review.

11.

Glycolipid binding preferences of Shiga toxin variants.

Karve SS, Weiss AA.

PLoS One. 2014 Jul 1;9(7):e101173. doi: 10.1371/journal.pone.0101173.

12.

Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure.

Porubsky S, Federico G, Müthing J, Jennemann R, Gretz N, Büttner S, Obermüller N, Jung O, Hauser IA, Gröne E, Geiger H, Gröne HJ, Betz C.

J Pathol. 2014 Sep;234(1):120-33. doi: 10.1002/path.4388.

13.

The ability of an attaching and effacing pathogen to trigger localized actin assembly contributes to virulence by promoting mucosal attachment.

Mallick EM, Garber JJ, Vanguri VK, Balasubramanian S, Blood T, Clark S, Vingadassalom D, Louissaint C, McCormick B, Snapper SB, Leong JM.

Cell Microbiol. 2014 Sep;16(9):1405-24. doi: 10.1111/cmi.12302.

14.

Recent advances in understanding enteric pathogenic Escherichia coli.

Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB.

Clin Microbiol Rev. 2013 Oct;26(4):822-80. doi: 10.1128/CMR.00022-13. Review.

15.

Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence.

Jandhyala DM, Vanguri V, Boll EJ, Lai Y, McCormick BA, Leong JM.

Infect Dis Clin North Am. 2013 Sep;27(3):631-49. doi: 10.1016/j.idc.2013.05.002. Review.

16.

Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells.

Amaral MM, Sacerdoti F, Jancic C, Repetto HA, Paton AW, Paton JC, Ibarra C.

PLoS One. 2013 Jul 30;8(7):e70431. doi: 10.1371/journal.pone.0070431.

17.

Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL.

Burlaka I, Liu XL, Rebetz J, Arvidsson I, Yang L, Brismar H, Karpman D, Aperia A.

J Am Soc Nephrol. 2013 Sep;24(9):1413-23. doi: 10.1681/ASN.2012101044.

18.

Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.

Ho NK, Henry AC, Johnson-Henry K, Sherman PM.

Can J Gastroenterol. 2013;27(5):281-5. Review.

19.

Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.

Yosief HO, Iyer SS, Weiss AA.

Infect Immun. 2013 Aug;81(8):2753-60. doi: 10.1128/IAI.00274-13.

20.

Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells.

Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, Würzner R, Orth-Höller D.

Infect Immun. 2013 Aug;81(8):2678-85. doi: 10.1128/IAI.01079-12.

Supplemental Content

Support Center